, a British biopharmaceutical company, has announced Series B investments of $20 million each from the and the .
The funds will enable Kymab to maximize the potential of its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet need. In addition, Kymab will collaborate with the Gates Foundation and its partners on vaccine antigen discovery research and development, with an initial focus on malaria and HIV.
The company is using its Kymouse platform to discover and develop fully human monoclonal antibody drugs — the best-selling classes of drugs, due in large part to their superior safety profiles. To complement the growth of its pipeline, Kymab will seek a limited number of strategic collaborations to identify and develop therapeutic antibodies for a range of diseases.
"We are excited to work with Kymab in pursuit of research and development of drugs and vaccines to address diseases that have a disproportionate impact on the world's poorest," said Trevor Mundel, president of global health at the Gates Foundation. "We believe Kymab has one of the most comprehensive transgenic technologies to date...and are pleased to support the company as it enters its next stage of growth."